{"id":"https://openalex.org/W2597590768","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.e13606","title":"Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis.","display_name":"Pharmacokinetic (PK) and pharmacodynamic (PD) analysis from a phase I study of PF-03446962, a fully human mab against ALK1, a TGF-beta receptor involved in tumor angiogenesis.","publication_year":2012,"publication_date":"2012-05-20","ids":{"openalex":"https://openalex.org/W2597590768","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.e13606","mag":"2597590768"},"language":"en","primary_location":{"id":"doi:10.1200/jco.2012.30.15_suppl.e13606","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.e13606","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.e13606","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"},"volume":null,"type":"conference-abstract","indexed_in":["crossref"],"open_access":{"is_oa":false,"oa_status":"closed","oa_url":null,"any_repository_has_fulltext":false},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5088976086","display_name":"Laura Williams Goff","orcid":"https://orcid.org/0000-0001-6719-1479","observed_orcids":["https://orcid.org/0000-0001-6719-1479"]},"institutions":[{"id":"https://openalex.org/I901861585","display_name":"Vanderbilt University Medical Center","ror":"https://ror.org/05dq2gs74","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Laura Williams Goff","raw_affiliation_strings":["Vanderbilt University Medical Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt University Medical Center, Nashville, TN","institution_ids":["https://openalex.org/I901861585"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5012061864","display_name":"Hossein Borghaei","orcid":"https://orcid.org/0000-0002-2577-4454","observed_orcids":["https://orcid.org/0000-0002-2577-4454"]},"institutions":[{"id":"https://openalex.org/I1289437631","display_name":"Fox Chase Cancer Center","ror":"https://ror.org/0567t7073","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I1289437631","https://openalex.org/I4210122924"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Hossein Borghaei","raw_affiliation_strings":["Fox Chase Cancer Center, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Fox Chase Cancer Center, Philadelphia, PA","institution_ids":["https://openalex.org/I1289437631"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5110382646","display_name":"Roger B. Cohen","orcid":"https://orcid.org/0009-0004-7423-2653","observed_orcids":["https://orcid.org/0009-0004-7423-2653"]},"institutions":[{"id":"https://openalex.org/I79576946","display_name":"University of Pennsylvania","ror":"https://ror.org/00b30xv10","country_code":"US","type":"education","lineage":["https://openalex.org/I79576946"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Roger B. Cohen","raw_affiliation_strings":["University of Pennsylvania, Philadelphia, PA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"University of Pennsylvania, Philadelphia, PA","institution_ids":["https://openalex.org/I79576946"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5039492614","display_name":"Jordan D. Berlin","orcid":"https://orcid.org/0000-0001-7571-2385","observed_orcids":["https://orcid.org/0000-0001-7571-2385"]},"institutions":[{"id":"https://openalex.org/I200719446","display_name":"Vanderbilt University","ror":"https://ror.org/02vm5rt34","country_code":"US","type":"education","lineage":["https://openalex.org/I200719446"]},{"id":"https://openalex.org/I4390039299","display_name":"Vanderbilt-Ingram Cancer Center","ror":"https://ror.org/02rjj2m04","country_code":"US","type":"healthcare","lineage":["https://openalex.org/I4210162197","https://openalex.org/I4390039299","https://openalex.org/I901861585"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Jordan Berlin","raw_affiliation_strings":["Vanderbilt-Ingram Cancer Center, Nashville, TN"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Vanderbilt-Ingram Cancer Center, Nashville, TN","institution_ids":["https://openalex.org/I200719446","https://openalex.org/I4390039299"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5034667041","display_name":"Cristina Noberasco","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Cristina Noberasco","raw_affiliation_strings":["European Institute of Oncology, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"European Institute of Oncology, Milan, Italy","institution_ids":["https://openalex.org/I6141010"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5031901871","display_name":"Corrado Gallo Stampino","orcid":null,"observed_orcids":[]},"institutions":[],"countries":[],"is_corresponding":false,"raw_author_name":"Corrado Gallo Stampino","raw_affiliation_strings":["Pfizer Inc., Milano, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., Milano, Italy","institution_ids":[]}]},{"author_position":"middle","author":{"id":null,"display_name":"Erjian Wang","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Erjian Wang","raw_affiliation_strings":["Pfizer Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":null,"display_name":"James Andrew Williams","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"James Andrew Williams","raw_affiliation_strings":["Pfizer Oncology, La Jolla, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Oncology, La Jolla, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5072627851","display_name":"Patricia A. English","orcid":null,"observed_orcids":[]},"institutions":[{"id":"https://openalex.org/I180857899","display_name":"Pfizer (United States)","ror":"https://ror.org/01xdqrp08","country_code":"US","type":"company","lineage":["https://openalex.org/I180857899"]}],"countries":["US"],"is_corresponding":false,"raw_author_name":"Patricia A English","raw_affiliation_strings":["Pfizer Inc., San Diego, CA"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Pfizer Inc., San Diego, CA","institution_ids":["https://openalex.org/I180857899"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5009935310","display_name":"Filippo de Braud","orcid":"https://orcid.org/0000-0003-0103-730X","observed_orcids":["https://orcid.org/0000-0003-0103-730X"]},"institutions":[{"id":"https://openalex.org/I6141010","display_name":"European Institute of Oncology","ror":"https://ror.org/02vr0ne26","country_code":"IT","type":"healthcare","lineage":["https://openalex.org/I4210153126","https://openalex.org/I6141010"]}],"countries":["IT"],"is_corresponding":false,"raw_author_name":"Filippo De Braud","raw_affiliation_strings":["European Institute of Oncology, Milan, Italy"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"European Institute of Oncology, Milan, Italy","institution_ids":["https://openalex.org/I6141010"]}]}],"institutions":[],"countries_distinct_count":2,"institutions_distinct_count":7,"corresponding_author_ids":[],"corresponding_institution_ids":[],"apc_list":null,"apc_paid":null,"fwci":null,"has_fulltext":false,"cited_by_count":1,"citation_normalized_percentile":null,"cited_by_percentile_year":null,"biblio":{"volume":"30","issue":"15_suppl","first_page":"e13606","last_page":"e13606"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T11501","display_name":"TGF-\u03b2 signaling in diseases","score":0.6845999956130981,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},"topics":[{"id":"https://openalex.org/T11501","display_name":"TGF-\u03b2 signaling in diseases","score":0.6845999956130981,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10422","display_name":"Angiogenesis and VEGF in Cancer","score":0.28999999165534973,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T12255","display_name":"Biosimilars and Bioanalytical Methods","score":0.0027000000700354576,"subfield":{"id":"https://openalex.org/subfields/2403","display_name":"Immunology"},"field":{"id":"https://openalex.org/fields/24","display_name":"Immunology and Microbiology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/alk1","display_name":"ALK1","score":0.8029999732971191},{"id":"https://openalex.org/keywords/tgf-beta-receptor","display_name":"TGF-beta receptor","score":0.7549999952316284},{"id":"https://openalex.org/keywords/monoclonal-antibodies","display_name":"monoclonal antibodies","score":0.8539999723434448},{"id":"https://openalex.org/keywords/tumor-angiogenesis","display_name":"tumor angiogenesis","score":0.9240000247955322},{"id":"https://openalex.org/keywords/pharmacokinetics","display_name":"pharmacokinetics","score":0.8889999985694885},{"id":"https://openalex.org/keywords/pharmacodynamics","display_name":"pharmacodynamics","score":0.9950000047683716},{"id":"https://openalex.org/keywords/solid-tumors","display_name":"solid tumors","score":0.6150000095367432},{"id":"https://openalex.org/keywords/hepatocellular-carcinoma","display_name":"hepatocellular carcinoma","score":0.9150000214576721},{"id":"https://openalex.org/keywords/non-small-cell-lung-cancer","display_name":"non-small cell lung cancer","score":0.890999972820282},{"id":"https://openalex.org/keywords/renal-cell-carcinoma","display_name":"renal cell carcinoma","score":0.9950000047683716},{"id":"https://openalex.org/keywords/vegfr-2-inhibitors","display_name":"VEGFR-2 inhibitors","score":0.7580000162124634},{"id":"https://openalex.org/keywords/anti-vegf-therapy","display_name":"anti-VEGF therapy","score":0.675000011920929},{"id":"https://openalex.org/keywords/soluble-vegfr1","display_name":"soluble VEGFR1","score":0.9079999923706055},{"id":"https://openalex.org/keywords/maximum-tolerated-dose","display_name":"maximum tolerated dose","score":0.6620000004768372},{"id":"https://openalex.org/keywords/anticancer-activity","display_name":"anticancer activity","score":0.8009999990463257},{"id":"https://openalex.org/keywords/time-to-progression","display_name":"time to progression","score":0.5049999952316284},{"id":"https://openalex.org/keywords/dose-limiting-toxicity","display_name":"dose-limiting toxicity","score":0.47600001096725464}],"concepts":[{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.7996314167976379},{"id":"https://openalex.org/C112705442","wikidata":"https://www.wikidata.org/wiki/Q323936","display_name":"Pharmacokinetics","level":2,"score":0.7765855193138123},{"id":"https://openalex.org/C22979827","wikidata":"https://www.wikidata.org/wiki/Q5137311","display_name":"Cmax","level":3,"score":0.6991342902183533},{"id":"https://openalex.org/C111113717","wikidata":"https://www.wikidata.org/wiki/Q725307","display_name":"Pharmacodynamics","level":3,"score":0.6278500556945801},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.6058739423751831},{"id":"https://openalex.org/C2780394083","wikidata":"https://www.wikidata.org/wiki/Q539568","display_name":"Angiogenesis","level":2,"score":0.5611056089401245},{"id":"https://openalex.org/C2778695046","wikidata":"https://www.wikidata.org/wiki/Q421136","display_name":"Sorafenib","level":3,"score":0.49624353647232056},{"id":"https://openalex.org/C2777288759","wikidata":"https://www.wikidata.org/wiki/Q4164182","display_name":"Dosing","level":2,"score":0.4474150240421295},{"id":"https://openalex.org/C170493617","wikidata":"https://www.wikidata.org/wiki/Q208467","display_name":"Receptor","level":2,"score":0.4164186120033264},{"id":"https://openalex.org/C42362537","wikidata":"https://www.wikidata.org/wiki/Q87099740","display_name":"Tyrosine kinase","level":3,"score":0.41185522079467773},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.40582144260406494},{"id":"https://openalex.org/C2778019345","wikidata":"https://www.wikidata.org/wiki/Q1148337","display_name":"Hepatocellular carcinoma","level":2,"score":0.0}],"mesh":[],"locations_count":1,"locations":[{"id":"doi:10.1200/jco.2012.30.15_suppl.e13606","doi":"https://doi.org/10.1200/jco.2012.30.15_suppl.e13606","is_oa":false,"landing_page_url":"https://doi.org/10.1200/jco.2012.30.15_suppl.e13606","pdf_url":null,"source":{"id":"https://openalex.org/S15137598","display_name":"Journal of Clinical Oncology","issn_l":"0732-183X","issn":["0732-183X","1527-7755"],"is_oa":false,"is_in_doaj":false,"is_core":true,"listed_in":["anvur-scientific","cwts-core","dongbi-a","doyens","jufo-3","ki-jl-3","medline","norway-2","poland-200","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310315671","host_organization_name":"Lippincott Williams & Wilkins","host_organization_lineage":["https://openalex.org/P4310315671","https://openalex.org/P4310318547"],"host_organization_lineage_names":["Lippincott Williams & Wilkins","Wolters Kluwer"],"type":"journal"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Journal of Clinical Oncology","raw_type":"journal-article"}],"best_oa_location":null,"sustainable_development_goals":[{"display_name":"Good health and well-being","id":"https://metadata.un.org/sdg/3","score":0.98580002784729}],"study_designs":[],"awards":[],"funders":[],"has_content":{"grobid_xml":false,"pdf":false},"content_urls":null,"referenced_works_count":0,"referenced_works":[],"related_works":["https://openalex.org/W4245464536","https://openalex.org/W2162766001","https://openalex.org/W2340207507","https://openalex.org/W2242531592","https://openalex.org/W2908236993","https://openalex.org/W2247505779","https://openalex.org/W2462071496","https://openalex.org/W2225574504","https://openalex.org/W164619530","https://openalex.org/W2074288357"],"abstract_inverted_index":{"e13606":[0],"Background:":[1],"The":[2,112],"proangiogenic":[3],"activity":[4,39],"of":[5,40,63,114,148,173,206,221,232,260,296,303,314],"Transforming":[6],"Growth":[7],"Factor":[8],"\u03b2":[9],"(TGF-\u03b2)":[10],"on":[11,37,65,91,103,177,318],"vasculature":[12],"is":[13,28,100,272],"exerted":[14],"by":[15],"selectively":[16],"binding":[17],"to":[18,69,79,131,236,285,323],"its":[19],"receptor,":[20],"activin":[21],"receptor":[22],"like":[23],"kinase":[24,143],"1":[25,45,234],"(ALK1).":[26],"PF-03446962":[27,41,64,99,271],"a":[29,43,170,204,273,325],"fully":[30],"human":[31],"mAb":[32],"against":[33],"ALK1.":[34],"Updated":[35],"results":[36],"anti-tumor":[38],"from":[42,268],"Phase":[44],"study":[46],"in":[47,159,209,279,287,289,333],"patients":[48,211],"(pts)":[49],"with":[50,56,77,166],"solid":[51],"tumors":[52],"are":[53,339],"reported":[54],"along":[55],"PK":[57,178],"and":[58,71,82,107,136,198,217,253,281,307,330],"PD":[59,297],"data.":[60],"Methods:":[61],"Effects":[62],"soluble":[66,224],"proteins":[67,227,265],"related":[68],"angiogenesis":[70],"the":[72,120,149,191,222,230,290],"TGF\u03b2":[73,246],"pathway":[74,264],"were":[75,126,212,283],"investigated":[76],"respect":[78],"PK,":[80],"PD,":[81],"antitumor":[83],"activity.":[84],"Results:":[85],"44":[86],"pts":[87,164,334],"have":[88],"been":[89],"enrolled":[90],"8":[92],"dose":[93,113,205,288,292],"levels":[94],"(0.5":[95],"-":[96],"15":[97],"mg/kg).":[98],"administered":[101],"i.v.":[102],"Day":[104],"1,":[105],"29":[106],"then":[108],"q":[109],"2":[110],"weeks.":[111],"10":[115,207,261],"mg/kg":[116,208],"was":[117,157],"defined":[118],"as":[119,146],"maximum":[121],"tolerated":[122],"dose.":[123],"3":[124],"PRs":[125],"observed:":[127],"one":[128,134,137],"HCC":[129,163],"resistant":[130],"anti-VEGF":[132],"therapy,":[133],"NSCLC":[135],"RCC":[138],"who":[139,335],"received":[140],"VEGFR2":[141,167],"tyrosine":[142],"inhibitors":[144],"(TKIs)":[145],"part":[147],"whole":[150],"previous":[151,300],"systemic":[152],"therapy.":[153],"SD":[154],"\u226516":[155],"weeks":[156],"observed":[158],"7/44":[160],"pts.":[161],"2/5":[162],"pre-treated":[165],"TKIs":[168,338],"showed":[169],"time-to-progression":[171],"(TTP)":[172],"5":[174],"months.":[175],"Based":[176,317],"data,":[179],"plasma":[180,226],"concentrations":[181,189],"at":[182,229],"4.5":[183],"-10mg/kg":[184],"doses":[185],"exceeded":[186],"predicted":[187],"efficacious":[188],"over":[190],"entire":[192],"dosing":[193],"period.":[194],"Cmax,":[195],"Tmax":[196],"AUC":[197,282],"terminal":[199],"elimination":[200],"half-life":[201],"values":[202,220,259],"following":[203,223],"7":[210],"290\u03bcg/mL,":[213],"1.5hrs,":[214],"40236":[215],"\u03bcg/mL*hr":[216],"302hrs.":[218],"Mean":[219],"(s)":[225],"increased":[228],"end":[231],"cycle":[233],"compared":[235],"baseline":[237],"(mean":[238],"value,":[239],"%":[240],"increase,":[241],"paired":[242],"t-test":[243],"p":[244],"value):":[245],"(+77%,":[247],"p=0.28),":[248],"sVEGF-A":[249],"(+60%,":[250],"p=":[251],"0.15),":[252],"sVEGFR1":[254],"(+113%,":[255],"p=0.10),":[256],"whereas":[257],"mean":[258],"other":[262],"angiogenesis/TGF\u03b2":[263],"changed":[266],"<20%":[267],"baseline.":[269],"Conclusions:":[270],"first-in-class":[274],"anti":[275],"ALK1":[276,306],"mAb.":[277],"Increases":[278],"Cmax":[280],"proportional":[284],"increases":[286],"therapeutic":[291],"range.":[293],"Preliminary":[294],"assessments":[295],"data":[298],"supports":[299],"laboratory":[301],"observations":[302],"interaction":[304],"between":[305],"VEGF":[308],"signalling":[309],"pathways":[310],"for":[311],"pericyte":[312],"protection":[313],"blood":[315],"vessels.":[316],"preliminary":[319],"results,":[320],"PF-0344692":[321],"appears":[322],"be":[324],"promising":[326],"novel":[327],"antiangiogenic":[328],"agent":[329],"further":[331],"investigations":[332],"failed":[336],"anti-VEGF/VEGFR2":[337],"warranted.":[340]},"counts_by_year":[{"year":2013,"cited_by_count":1}],"updated_date":"2026-10-27T15:51:10.671819","created_date":"2017-04-07T00:00:00"}